$SYRE News

Mizuho Maintains Outperform on Spyre Therapeutics, Raises Price Target to $120

Spyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting Data

Spyre Therapeutics Files Prospectus For Offering Mixed Shelf; Terms Undisclosed

Spyre Therapeutics: A Platform Where The Combination Strategy Is The Real Asset

What's Going On With Spyre Therapeutics Stock On Wednesday?

Deutsche Bank Maintains Buy on Spyre Therapeutics, Raises Price Target to $135

Spyre Therapeutics Announces 12-Week Induction Data From Part A Of Phase 2 SKYLINE Study Of SPY002 To Treat Active Ulcerative Colitis Meets Primary Endpoint; SPY002 Well Tolerated With Consistent Safety Profile

Spyre Therapeutics, Inc. (SYRE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Deutsche Bank Maintains Buy on Spyre Therapeutics, Raises Price Target to $115

Spyre Therapeutics Completes Enrollment For All Sub-Studies In SKYWAY Basket Trial Of SPY072 In Rheumatic Diseases

Why Spyre Therapeutics (SYRE) Is Down 6.1% After Broadening Its SPY003 Paragon License Terms

Spyre Therapeutics Expands SPY003 Rights Beyond IBD Through Amended Paragon License Agreement

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares

This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million

Citigroup Maintains Buy on Spyre Therapeutics, Raises Price Target to $97

Stifel Maintains Buy on Spyre Therapeutics, Raises Price Target to $107

Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Spyre Therapeutics Q1 EPS $(0.74) Misses $(0.68) Estimate

Spyre Therapeutics Announces Grants of Inducement Awards